Magnitude, Distribution and Contextual Risk Enhancing Predictors of High 10-Year Cardiovascular Risk Among Diabetic Patients in Tanzania

References

• Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157:107843. doi:10.1016/j.diabres.2019.107843
   PubMed Web of Science ®Google Scholar
• Ogurtsova K, Guariguata L, Barengo NC, et al. IDF Diabetes Atlas: global estimates of undiagnosed diabetes in adults for 2021. Diabetes Res Clin Pract. 2022;183:109118. doi:10.1016/j.diabres.2021.109118
   PubMed Web of Science ®Google Scholar
• Zhao Y, Xiang P, Coll B, Lopez JAG, Wong ND. Diabetes associated residual atherosclerotic cardiovascular risk in statin-treated patients with prior atherosclerotic cardiovascular disease. J Diabetes Complications. 2021;35(3):107767. doi:10.1016/j.jdiacomp.2020.107767
   PubMed Web of Science ®Google Scholar
• Raghavan S, Vassy JL, Ho YL, et al. Diabetes mellitus-related all-cause and cardiovascular mortality in a national cohort of adults. J Am Heart Assoc. 2019;8(4):e011295. doi:10.1161/JAHA.118.011295
   PubMed Web of Science ®Google Scholar
• Wong ND, Budoff MJ, Ferdinand K, et al. Atherosclerotic cardiovascular disease risk assessment: an American Society for Preventive Cardiology clinical practice statement. Am J Prev Cardiol. 2022;10:100335. doi:10.1016/j.ajpc.2022.100335
   PubMedGoogle Scholar
• Mbanya JC, Motala AA, Sobngwi E, Assah FK, Enoru ST. Diabetes in sub-Saharan Africa. Lancet. 2010;375(9733):2254–2266. doi:10.1016/S0140-6736(10)60550-8
   PubMed Web of Science ®Google Scholar
• Mayige M, Kagaruki G, Ramaiya K, Swai A. Non communicable diseases in Tanzania: a call for urgent action. Tanzan J Health Res. 2011;13(5 Suppl 1):378–386. doi:10.4314/thrb.v13i5.7
   PubMedGoogle Scholar
• Mfinangai SG, Kivuyo SL, Ezekiel L, Ngadaya E, Mghamba J, Ramaiya K. Public health concern and initiatives on the priority action towards non-communicable diseases in Tanzania. Tanzan J Health Res. 2011;13(5 Suppl 1):365–377.
   PubMedGoogle Scholar
• Chillo P, Mashili F, Kwesigabo G, Ruggajo P, Kamuhabwa A. Developing a sustainable cardiovascular disease research strategy in Tanzania through training: leveraging from the East African Centre of Excellence in cardiovascular sciences project. Front Cardiovasc Med. 2022;9:849007. doi:10.3389/fcvm.2022.849007
   PubMed Web of Science ®Google Scholar
• Polonsky TS, Khera A, Miedema MD, Schocken DD, Wilson PWF. Highlights in ASCVD primary prevention for 2021. J Am Heart Assoc. 2022;11(13):e025973. doi:10.1161/JAHA.122.025973
   PubMed Web of Science ®Google Scholar
• DeFilippis AP, Young R, Carrubba CJ, et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med. 2015;162(4):266–275. doi:10.7326/M14-1281
   PubMed Web of Science ®Google Scholar
• Bazo-Alvarez JC, Quispe R, Peralta F, et al. Agreement between cardiovascular disease risk scores in resource-limited settings: evidence from 5 Peruvian sites. Crit Pathw Cardiol. 2015;14(2):74–80. doi:10.1097/HPC.0000000000000045
   PubMedGoogle Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019;139(25):e1082–e143. doi:10.1161/CIR.0000000000000625
   PubMed Web of Science ®Google Scholar
• Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49–S73. doi:10.1161/01.cir.0000437741.48606.98
   PubMed Web of Science ®Google Scholar
• Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019;140(11):e596–e646. doi:10.1161/CIR.0000000000000678
   PubMed Web of Science ®Google Scholar
• Clark AM, DesMeules M, Luo W, Duncan AS, Wielgosz A. Socioeconomic status and cardiovascular disease: risks and implications for care. Nat Rev Cardiol. 2009;6(11):712–722. doi:10.1038/nrcardio.2009.163
   PubMed Web of Science ®Google Scholar
• Minja NW, Nakagaayi D, Aliku T, et al. Cardiovascular diseases in Africa in the twenty-first century: gaps and priorities going forward. Front Cardiovasc Med. 2022;9:1008335. doi:10.3389/fcvm.2022.1008335
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):3168–3209. doi:10.1016/j.jacc.2018.11.002
   PubMed Web of Science ®Google Scholar
• Martin-Timon I, Sevillano-Collantes C, Segura-Galindo A, Del Canizo-Gomez FJ. Type 2 diabetes and cardiovascular disease: have all risk factors the same strength? World J Diabetes. 2014;5(4):444–470. doi:10.4239/wjd.v5.i4.444
   PubMedGoogle Scholar
• Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of Sodium Glucose Co-Transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5(6):632–644. doi:10.1016/j.jacbts.2020.02.004
   PubMedGoogle Scholar
• Kyriakos G, Quiles-Sanchez LV, Garmpi A, et al. SGLT2 inhibitors and cardiovascular outcomes: do they differ or there is a class effect? New insights from the EMPA-REG OUTCOME trial and the CVD-REAL study. Curr Cardiol Rev. 2020;16(4):258–265. doi:10.2174/1573403X15666190730094215
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. doi:10.1056/NEJMoa1603827
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–130. doi:10.1016/S0140-6736(19)31149-3
   PubMed Web of Science ®Google Scholar
• Kanie T, Mizuno A, Takaoka Y, et al. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. Cochrane Database Syst Rev. 2021;10:CD013650. doi:10.1002/14651858.CD013650.pub2
   PubMedGoogle Scholar
• Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N. Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. Arch Intern Med. 2011;171(5):404–410. doi:10.1001/archinternmed.2011.2
   PubMedGoogle Scholar
• Banerjee C, Moon YP, Paik MC, et al. Duration of diabetes and risk of ischemic stroke: the Northern Manhattan Study. Stroke. 2012;43(5):1212–1217. doi:10.1161/STROKEAHA.111.641381
   PubMed Web of Science ®Google Scholar
• Soyoye DO, Abiodun OO, Ikem RT, Kolawole BA, Akintomide AO. Diabetes and peripheral artery disease: a review. World J Diabetes. 2021;12(6):827–838. doi:10.4239/wjd.v12.i6.827
   PubMed Web of Science ®Google Scholar
• Sarwar N, Gao P, Seshasai SR, et al.; Emerging Risk Factors C. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–2222. doi:10.1016/S0140-6736(10)60484-9
   PubMed Web of Science ®Google Scholar
• Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease: a possible marker for increased risk of stroke. Stroke. 1997;28(3):557–563. doi:10.1161/01.STR.28.3.557
   PubMed Web of Science ®Google Scholar
• Mlekusch W, Exner M, Sabeti S, et al. Serum creatinine predicts mortality in patients with peripheral artery disease: influence of diabetes and hypertension. Atherosclerosis. 2004;175(2):361–367. doi:10.1016/j.atherosclerosis.2004.04.008
   PubMed Web of Science ®Google Scholar
• Schneider C, Coll B, Jick SS, Meier CR. Doubling of serum creatinine and the risk of cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes mellitus: a cohort study. Clin Epidemiol. 2016;8:177–184. doi:10.2147/CLEP.S107060
   PubMed Web of Science ®Google Scholar
• Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339–352. doi:10.1016/S0140-6736(13)60595-4
   PubMed Web of Science ®Google Scholar
• National Kidney F. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–S266.
   PubMed Web of Science ®Google Scholar
• Weir MR. Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol. 2007;2(3):581–590. doi:10.2215/CJN.03190906
   PubMed Web of Science ®Google Scholar
• Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157(4):263–275. doi:10.7326/0003-4819-157-4-201208210-00007
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–952. doi:10.1016/S0140-6736(04)17018-9
   PubMed Web of Science ®Google Scholar
• Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–2472. doi:10.1093/eurheartj/ehx144
   PubMed Web of Science ®Google Scholar
• Mihaylova B, Emberson J, Blackwell L, et al.; Cholesterol Treatment Trialists C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–590.
   PubMed Web of Science ®Google Scholar